INDOLENT NON-HODGKIN LYMPHOMA
Clinical trials for INDOLENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new INDOLENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for INDOLENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy-Chemo combo shows promise for tough lymphoma
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can help people with aggressive B-cell non-Hodgkin lymphoma. About 30 adults with advanced stages of the disease will receive the combination, followed by a short cours…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 26, 2026 06:12 UTC
-
New hope for aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combination improves treatment response. About 50 adults will take p…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 06:06 UTC
-
Two-Drug combo shows promise for aggressive blood cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with certain types of blood cancer that have changed into a more aggressive form (Richter's transformation or transformed non-Hodgkin lymphoma). The goal is to find the best dose and see …
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 06:01 UTC
-
New immunotherapy cocktail aims to tackle lymphoma without chemo
Disease control OngoingThis study tests whether combining two immunotherapy drugs, glofitamab and obinutuzumab, can safely and effectively treat people newly diagnosed with follicular lymphoma or marginal zone lymphoma. The 47 participants have not had any prior lymphoma treatment. The goal is to see i…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New drug duo shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how well the drugs shrink or eliminate cancer. About 30 adults with newly diagnosed lymphoma will receive this t…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Cancer drug trial pulled before it even started
Disease control TerminatedThis was a Phase I trial testing a drug called CB-5339 in people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the best dose and check for side effects. However, the study was withdrawn before enrolling any partic…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:21 UTC